APP and Alzheimer disease: For this reason, treatments for AD have focused on inhibiting the excessive deposition of Aβ and tau proteins, leading to the development of BACE1 inhibitors such as Verubecestat, Atabecestat, and Elenbecestat, which target β-secretase to cleave APP and inhibit the production of Aβ protein [33].